PL3752496T3 - Sposoby i związki pośrednie do wytwarzania związku terapeutycznego przydatnego w leczeniu infekcji wirusowej retroviridae - Google Patents
Sposoby i związki pośrednie do wytwarzania związku terapeutycznego przydatnego w leczeniu infekcji wirusowej retroviridaeInfo
- Publication number
- PL3752496T3 PL3752496T3 PL19707677.1T PL19707677T PL3752496T3 PL 3752496 T3 PL3752496 T3 PL 3752496T3 PL 19707677 T PL19707677 T PL 19707677T PL 3752496 T3 PL3752496 T3 PL 3752496T3
- Authority
- PL
- Poland
- Prior art keywords
- intermediates
- preparing
- treatment
- methods
- viral infection
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/65—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by splitting-off hydrogen atoms or functional groups; by hydrogenolysis of functional groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
- C07C59/50—Mandelic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/06—Five-membered rings having the hetero atoms in positions 1 and 3, e.g. cyclic dithiocarbonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862710575P | 2018-02-16 | 2018-02-16 | |
| PCT/US2019/018323 WO2019161280A1 (en) | 2018-02-16 | 2019-02-15 | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3752496T3 true PL3752496T3 (pl) | 2023-11-27 |
Family
ID=65529928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19707677.1T PL3752496T3 (pl) | 2018-02-16 | 2019-02-15 | Sposoby i związki pośrednie do wytwarzania związku terapeutycznego przydatnego w leczeniu infekcji wirusowej retroviridae |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US10696657B2 (pl) |
| EP (2) | EP4253366A3 (pl) |
| JP (4) | JP7038843B2 (pl) |
| KR (3) | KR102847339B1 (pl) |
| CN (2) | CN112055712B (pl) |
| AR (1) | AR114631A1 (pl) |
| AU (3) | AU2019222559B2 (pl) |
| CA (4) | CA3175384A1 (pl) |
| ES (1) | ES2956288T3 (pl) |
| PL (1) | PL3752496T3 (pl) |
| TW (4) | TWI745652B (pl) |
| WO (1) | WO2019161280A1 (pl) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2729448E (pt) | 2011-07-06 | 2015-12-02 | Gilead Sciences Inc | Compostos para o tratamento de vih |
| JP6716785B2 (ja) | 2016-08-19 | 2020-07-01 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物 |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| TWI687415B (zh) | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| ES2958828T3 (es) | 2018-02-15 | 2024-02-15 | Gilead Sciences Inc | Derivados de piridina y su uso para tratar una infección por VIH |
| PL3752496T3 (pl) * | 2018-02-16 | 2023-11-27 | Gilead Sciences, Inc. | Sposoby i związki pośrednie do wytwarzania związku terapeutycznego przydatnego w leczeniu infekcji wirusowej retroviridae |
| CN120078775A (zh) | 2018-07-16 | 2025-06-03 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| WO2020053811A1 (en) | 2018-09-14 | 2020-03-19 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| WO2020058844A1 (en) | 2018-09-20 | 2020-03-26 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| PE20211781A1 (es) | 2018-10-24 | 2021-09-08 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicacion del virus de la inmunodeficiencia humana |
| EP3870576B1 (en) | 2018-10-24 | 2024-01-24 | VIIV Healthcare UK (No.5) Limited | Bezopyrazole derivatives as inhibitors of human immunodeficiency virus replication |
| JP7500555B2 (ja) | 2018-10-25 | 2024-06-17 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| ES2969030T3 (es) | 2018-10-29 | 2024-05-16 | Viiv Healthcare Uk No 5 Ltd | Derivados de quinazolinil-indazol y su uso como inhibidores de replicación de virus de inmunodeficiencia humana |
| WO2020095176A1 (en) | 2018-11-05 | 2020-05-14 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| EP3877387A1 (en) | 2018-11-05 | 2021-09-15 | ViiV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| UY38559A (es) | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| US20220409619A1 (en) | 2019-10-01 | 2022-12-29 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| JP2022551254A (ja) | 2019-10-01 | 2022-12-08 | ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド | ヒト免疫不全ウイルスの複製阻害剤 |
| TW202128648A (zh) | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| EP4041729B1 (en) | 2019-10-08 | 2023-09-27 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| AU2020391466B2 (en) | 2019-11-26 | 2024-05-23 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of HIV |
| WO2021176367A1 (en) | 2020-03-06 | 2021-09-10 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| CA3170536A1 (en) | 2020-03-06 | 2021-09-10 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| AU2021256166B2 (en) | 2020-04-15 | 2024-05-23 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| WO2021236944A1 (en) | 2020-05-21 | 2021-11-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
| CA3181690A1 (en) | 2020-06-25 | 2021-12-30 | Chienhung CHOU | Capsid inhibitors for the treatment of hiv |
| PL4445900T3 (pl) | 2021-12-03 | 2025-09-22 | Gilead Sciences, Inc. | Związki terapeutyczne przeciwko zakażeniu wirusem hiv |
| WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| WO2023102529A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| CN116285754B (zh) * | 2023-04-18 | 2025-05-09 | 安徽禾臣新材料有限公司 | 一种电子显示屏用的吸附垫及其制备工艺 |
| AU2024259111A1 (en) | 2023-04-19 | 2025-10-16 | Gilead Sciences, Inc. | Dosing regimen of capsid inhibitor |
| US20250011352A1 (en) | 2023-05-31 | 2025-01-09 | Gilead Sciences, Inc. | Solid forms |
| WO2024249672A1 (en) | 2023-05-31 | 2024-12-05 | Gilead Sciences, Inc. | Process of preparing hiv capsid inhibitor |
| CN116675675A (zh) * | 2023-06-05 | 2023-09-01 | 北京康立生医药技术开发有限公司 | 一种艾滋病治疗药物来那卡帕韦中间体化合物的制备方法 |
| AR132951A1 (es) | 2023-06-15 | 2025-08-13 | Viiv Healthcare Uk No 5 Ltd | Métodos e intermedios para preparar compuestos |
| WO2025029247A1 (en) | 2023-07-28 | 2025-02-06 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| CN118126057B (zh) * | 2024-05-06 | 2024-07-19 | 四川大学华西第二医院 | 一种化合物RCPH及其合成方法、作为比率型pH探针的应用和产品 |
| WO2025240393A1 (en) | 2024-05-14 | 2025-11-20 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| US20250367386A1 (en) | 2024-05-14 | 2025-12-04 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| WO2025240389A1 (en) | 2024-05-14 | 2025-11-20 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| WO2025240387A1 (en) | 2024-05-14 | 2025-11-20 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| WO2025240385A1 (en) | 2024-05-14 | 2025-11-20 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| CN118599802B (zh) * | 2024-08-08 | 2024-10-18 | 爱斯特（成都）生物制药股份有限公司 | 一种转氨酶、其制备方法、其应用，编码转氨酶的基因，重组质粒，重组菌，制备(s)-3-氨基丁酸的方法 |
Family Cites Families (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1017198A (en) | 1910-07-13 | 1912-02-13 | Elmore W Bender | Electric motor-vehicle. |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| DE69115694T2 (de) | 1990-06-13 | 1996-10-17 | Arnold Newton Mass. Glazier | Phosphorylierte prodrugs |
| DE10399025I2 (de) | 1990-09-14 | 2007-11-08 | Acad Of Science Czech Republic | Wirkstoffvorläufer von Phosphonaten |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| EP2682397B1 (en) | 2000-07-21 | 2017-04-19 | Gilead Sciences, Inc. | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| US7183290B2 (en) | 2001-06-27 | 2007-02-27 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| US7196201B2 (en) | 2001-06-27 | 2007-03-27 | Smithkline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
| DK1441734T3 (da) | 2001-10-26 | 2007-06-11 | Angeletti P Ist Richerche Bio | Dihydroxypyrimidin-carboxamid-inhibitorer a HIV-integrase |
| US7642277B2 (en) | 2002-12-04 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
| US20040186151A1 (en) | 2003-02-12 | 2004-09-23 | Mjalli Adnan M.M. | Substituted azole derivatives as therapeutic agents |
| AU2004233898B2 (en) | 2003-04-25 | 2010-12-23 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| CN1972956A (zh) | 2004-02-27 | 2007-05-30 | 先灵公司 | 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的新化合物 |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| ES2363160T3 (es) | 2004-07-27 | 2011-07-22 | Gilead Sciences, Inc. | Conjugados de fosfonato nucelosidico como agentes anti-vih. |
| US20080318999A1 (en) | 2005-08-05 | 2008-12-25 | Methvin Isaac | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators |
| TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯 |
| TW201402124A (zh) | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯 |
| CA2633252A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| BRPI0710487A2 (pt) | 2006-04-12 | 2012-06-05 | Merck & Co Inc | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitácel do mesmo e, método para tratar ou controlar a epilepsia e a dor e para o tratamento ou prevenção de um distúrbio do sono em um paciente. |
| WO2008013622A2 (en) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| US8193225B2 (en) | 2006-10-13 | 2012-06-05 | The Board Of Regents Of The University Of Texas System | Isoxazole amides, derivatives and methods of chemical induction of neurogenesis |
| US8124811B2 (en) | 2007-03-20 | 2012-02-28 | Allylix, Inc. | Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one |
| JP5465667B2 (ja) | 2007-06-29 | 2014-04-09 | ギリアード サイエンシーズ， インコーポレイテッド | 抗ウイルス化合物 |
| US8927569B2 (en) | 2007-07-19 | 2015-01-06 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as antiviral agents |
| BRPI0818244A2 (pt) | 2007-10-24 | 2015-06-16 | Merck Sharp & Dohme | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença |
| WO2009054983A1 (en) | 2007-10-24 | 2009-04-30 | Merck & Co., Inc. | Heterocycle amide t-type calcium channel antagonists |
| WO2009062285A1 (en) | 2007-11-16 | 2009-05-22 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| JP5537442B2 (ja) | 2008-03-13 | 2014-07-02 | ブリストル−マイヤーズ スクイブ カンパニー | 第ｘｉａ因子阻害剤としてのピリダジン誘導体 |
| WO2010014913A1 (en) | 2008-08-01 | 2010-02-04 | Ventirx Pharmaceuticals, Inc. | Toll-like receptor agonist formulations and their use |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| NZ593110A (en) | 2008-12-09 | 2013-06-28 | Gilead Sciences Inc | pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS |
| EP2401286A4 (en) | 2009-02-25 | 2012-09-26 | Bigtec Private Ltd | PROBES AND PRIMERS FOR DETECTION OF CHIKUNGUNYA |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| CN102781933B (zh) | 2009-08-18 | 2016-01-20 | 文蒂雷克斯药品公司 | 作为toll样受体调节剂的取代的苯并氮杂* |
| RU2016125705A (ru) | 2009-08-18 | 2018-12-04 | Вентиркс Фармасьютикалз, Инк. | Замещенные бензоазепины в качестве модуляторов тoll-подобных рецепторов |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| US20130165489A1 (en) | 2010-05-03 | 2013-06-27 | The Trustees Of The University Of Pennsylvania | Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof |
| WO2011143772A1 (en) | 2010-05-21 | 2011-11-24 | Boehringer Ingelheim International Gmbh | Inhibitors of hiv replication |
| WO2012003498A1 (en) | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds |
| MA34397B1 (fr) | 2010-07-02 | 2013-07-03 | Gilead Sciences Inc | Dérivés d'acide napht-2-ylacétique dans le traitement du sida |
| RU2016141322A (ru) | 2010-10-01 | 2018-12-14 | Вентиркс Фармасьютикалз, Инк. | Терапевтическое применение агониста tlr и комбинированная терапия |
| CA2812787A1 (en) | 2010-10-01 | 2012-04-05 | Robert Hershberg | Methods for the treatment of allergic diseases |
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| CN103562186B (zh) | 2011-01-12 | 2017-02-15 | 帆德制药股份有限公司 | 作为toll样受体调节剂的取代的苯并氮杂卓 |
| BR112013017947A2 (pt) | 2011-01-12 | 2018-12-18 | Array Biopharma Inc | benzoazepinas substituídas como moduladores de receptor toll-like |
| US8835488B2 (en) | 2011-03-23 | 2014-09-16 | Trevena, Inc. | Opioid receptor ligands and methods of using and making same |
| MY170941A (en) | 2011-04-08 | 2019-09-19 | Janssen Sciences Ireland Uc | Pyrimidine derivatives for the treatment of viral infections |
| WO2012145728A1 (en) | 2011-04-21 | 2012-10-26 | Gilead Sciences, Inc. | Benzothiazole compounds and their pharmaceutical use |
| BR112013029537B1 (pt) | 2011-05-18 | 2020-06-30 | Janssen Sciences Ireland Uc | derivados de quinazolina, seu uso no tratamento de infecções virais e outras doenças e composição farmacêutica que os compreende |
| PT2729448E (pt) * | 2011-07-06 | 2015-12-02 | Gilead Sciences Inc | Compostos para o tratamento de vih |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| UA115311C2 (uk) | 2011-08-16 | 2017-10-25 | Гіліад Сайєнсіз, Інк. | Геміфумарат тенофовіру алафенаміду |
| WO2013091096A1 (en) | 2011-12-20 | 2013-06-27 | Boehringer Ingelheim International Gmbh | Condensed triclyclic compounds as inhibitors of hiv replication |
| EA026368B1 (ru) | 2011-12-21 | 2017-03-31 | Новира Терапьютикс, Инк. | Противовирусные агенты против гепатита в |
| SG11201404743TA (en) | 2012-02-08 | 2014-09-26 | Janssen R & D Ireland | Piperidino-pyrimidine derivatives for the treatment of viral infections |
| EP3070081B1 (en) | 2012-04-20 | 2018-02-28 | Gilead Sciences, Inc. | Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection |
| GB201213087D0 (en) | 2012-07-24 | 2012-09-05 | Medical Res Council | Inhibition of HIV-1 infection |
| WO2014023813A1 (en) | 2012-08-10 | 2014-02-13 | Janssen R&D Ireland | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases |
| WO2014028931A2 (en) | 2012-08-17 | 2014-02-20 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| MX365114B (es) | 2012-10-10 | 2019-05-23 | Janssen Sciences Ireland Uc | Derivados pirrolo[3,2-d]pirimidinicos para el tratamiento de infecciones viricas y otras enfermedades. |
| MY171115A (en) | 2012-11-16 | 2019-09-26 | Janssen Sciences Ireland Uc | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
| DK3067358T3 (da) | 2012-12-21 | 2019-11-04 | Gilead Sciences Inc | Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse |
| SG11201504982PA (en) | 2012-12-27 | 2015-07-30 | Japan Tobacco Inc | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR |
| JP5941598B2 (ja) | 2013-01-09 | 2016-06-29 | ギリアード サイエンシーズ， インコーポレイテッド | ５員ヘテロアリールおよびそれらの抗ウイルス剤としての使用 |
| NZ727792A (en) | 2013-01-09 | 2018-04-27 | Gilead Sciences Inc | Therapeutic compounds |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| WO2014110323A1 (en) | 2013-01-11 | 2014-07-17 | Johnson Controls Technology Company | Vehicle interior component having a wireless charging indicator |
| UA118751C2 (uk) | 2013-02-21 | 2019-03-11 | ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі | Похідні 2-амінопіримідину для лікування вірусних інфекцій |
| TWI694071B (zh) * | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| US20140296266A1 (en) | 2013-03-01 | 2014-10-02 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2014165128A2 (en) | 2013-03-12 | 2014-10-09 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
| GB201312991D0 (en) | 2013-07-19 | 2013-09-04 | Isis Innovation | Process |
| MX2016004492A (es) | 2013-10-24 | 2016-06-16 | Squibb Bristol Myers Co | Inhibidores de la replicacion del virus de inmunodeficiencia humana (vih). |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| PT3186239T (pt) * | 2014-08-29 | 2019-01-10 | Gilead Sciences Inc | Agentes antirretrovirais |
| US9855230B2 (en) | 2014-09-09 | 2018-01-02 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| TWI770552B (zh) | 2014-12-24 | 2022-07-11 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| SG11201705192PA (en) | 2014-12-24 | 2017-07-28 | Gilead Sciences Inc | Fused pyrimidine compounds for the treatment of hiv |
| AU2016216673B2 (en) | 2015-03-04 | 2017-02-02 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| KR20180005673A (ko) | 2015-04-23 | 2018-01-16 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제 억제제 |
| AU2016250662A1 (en) | 2015-04-23 | 2017-11-16 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| CN109879859B (zh) | 2015-07-06 | 2022-01-25 | 吉利德科学公司 | Cot调节剂及其使用方法 |
| JP6716785B2 (ja) | 2016-08-19 | 2020-07-01 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物 |
| AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| JOP20180009A1 (ar) | 2017-02-06 | 2019-01-30 | Gilead Sciences Inc | مركبات مثبط فيروس hiv |
| TW201906834A (zh) | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| TWI687415B (zh) | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| ES2958828T3 (es) | 2018-02-15 | 2024-02-15 | Gilead Sciences Inc | Derivados de piridina y su uso para tratar una infección por VIH |
| PL3752496T3 (pl) | 2018-02-16 | 2023-11-27 | Gilead Sciences, Inc. | Sposoby i związki pośrednie do wytwarzania związku terapeutycznego przydatnego w leczeniu infekcji wirusowej retroviridae |
| US10911396B2 (en) | 2018-06-28 | 2021-02-02 | Paypal, Inc. | Mid-tier messaging system |
| CN120078775A (zh) | 2018-07-16 | 2025-06-03 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| AU2020391466B2 (en) | 2019-11-26 | 2024-05-23 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of HIV |
| CA3181690A1 (en) | 2020-06-25 | 2021-12-30 | Chienhung CHOU | Capsid inhibitors for the treatment of hiv |
| PL4445900T3 (pl) | 2021-12-03 | 2025-09-22 | Gilead Sciences, Inc. | Związki terapeutyczne przeciwko zakażeniu wirusem hiv |
-
2019
- 2019-02-15 PL PL19707677.1T patent/PL3752496T3/pl unknown
- 2019-02-15 CN CN201980026177.XA patent/CN112055712B/zh active Active
- 2019-02-15 KR KR1020237033998A patent/KR102847339B1/ko active Active
- 2019-02-15 TW TW108105148A patent/TWI745652B/zh active
- 2019-02-15 CA CA3175384A patent/CA3175384A1/en active Pending
- 2019-02-15 CN CN202310818078.3A patent/CN116854630A/zh active Pending
- 2019-02-15 WO PCT/US2019/018323 patent/WO2019161280A1/en not_active Ceased
- 2019-02-15 US US16/277,552 patent/US10696657B2/en active Active
- 2019-02-15 KR KR1020207026307A patent/KR102587504B1/ko active Active
- 2019-02-15 TW TW112125257A patent/TWI866322B/zh active
- 2019-02-15 ES ES19707677T patent/ES2956288T3/es active Active
- 2019-02-15 EP EP23183317.9A patent/EP4253366A3/en active Pending
- 2019-02-15 AU AU2019222559A patent/AU2019222559B2/en active Active
- 2019-02-15 TW TW110139864A patent/TWI823164B/zh active
- 2019-02-15 JP JP2020543581A patent/JP7038843B2/ja active Active
- 2019-02-15 AR ARP190100396A patent/AR114631A1/es not_active Application Discontinuation
- 2019-02-15 TW TW113143742A patent/TW202535848A/zh unknown
- 2019-02-15 CA CA3090280A patent/CA3090280C/en active Active
- 2019-02-15 EP EP19707677.1A patent/EP3752496B1/en active Active
- 2019-02-15 CA CA3175557A patent/CA3175557A1/en active Pending
- 2019-02-15 KR KR1020257026966A patent/KR20250126866A/ko active Pending
- 2019-02-15 CA CA3281991A patent/CA3281991A1/en active Pending
-
2020
- 2020-05-08 US US16/869,653 patent/US11117886B2/en active Active
-
2021
- 2021-06-16 US US17/349,288 patent/US11760746B2/en active Active
- 2021-12-28 JP JP2021214246A patent/JP7269316B2/ja active Active
-
2022
- 2022-03-15 JP JP2022040194A patent/JP7394901B2/ja active Active
- 2022-04-19 AU AU2022202535A patent/AU2022202535B2/en active Active
-
2023
- 2023-06-05 US US18/205,877 patent/US12122765B2/en active Active
- 2023-11-28 JP JP2023200552A patent/JP7749642B2/ja active Active
-
2024
- 2024-03-28 AU AU2024202049A patent/AU2024202049A1/en active Pending
- 2024-09-10 US US18/829,547 patent/US20250100999A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3752496T3 (pl) | Sposoby i związki pośrednie do wytwarzania związku terapeutycznego przydatnego w leczeniu infekcji wirusowej retroviridae | |
| EP3490987A4 (en) | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF HBV INFECTION. | |
| IL269927A (en) | Methods of treating patients with hepatitis B virus infection | |
| IL290999A (en) | hbv vaccines and hbv treatment methods | |
| IL292810A (en) | Therapeutic compounds and methods of use | |
| IL284047A (en) | Combined treatment of HBV | |
| EP3773753A4 (en) | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS | |
| IL287423A (en) | Antibodies and methods for treating influenza E infection | |
| IL291601B1 (en) | Neoglycoconjugates as vaccines and therapeutic tools | |
| EP3773659A4 (en) | METHODS OF TREATMENT OF HBV INFECTION | |
| IL272094A (en) | Antibodies and methods for the diagnosis and treatment of hepatitis B virus infection | |
| IL279078A (en) | Combination therapy for the treatment of hepatitis B viral infection | |
| GB201803197D0 (en) | Viral treatment | |
| HUE069820T2 (hu) | Nalfurafin alkalmazása demielinizációs betegségek kezelésére | |
| HK40095795A (zh) | 用於制备可用於治疗逆转录病毒科病毒感染的治疗性化合物的方法和中间体 | |
| DK4054582T3 (da) | Terapeutiske kombinationer af acalabrutinib og capivasertib til behandling af b-celle-maligniteter | |
| GB201812861D0 (en) | Methods of administering therapy | |
| IL289069A (en) | Synergistic effect of fxr and ifn agonist for treatment of HBV infection | |
| GB2603379B (en) | Avocatin B for the treatment of diseases and conditions | |
| PL3810625T3 (pl) | Sposoby i kompozycje do leczenia zakażenia wirusem zapalenia wątroby typu b | |
| HK40102383A (zh) | Hbv疫苗和治疗hbv的方法 | |
| HK40113589A (zh) | Hbv疫苗和治疗hbv的方法 | |
| HK40119384A (zh) | Hbv疫苗和治疗hbv的方法 | |
| GB202315114D0 (en) | Viral treatment | |
| HK40068232A (en) | Therapeutic viral vaccine |